Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis
Synovial fibroblasts (SFs) are key pathogenic drivers in rheumatoid arthritis (RA). Their in vivo activation by TNF is sufficient to orchestrate full arthritic pathogenesis in animal models, and TNF blockade proved efficacious for a high percentage of patients with RA albeit coinducing rare but seri...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Clinical investigation
2023-05-01
|
| Series: | JCI Insight |
| Subjects: | |
| Online Access: | https://doi.org/10.1172/jci.insight.165024 |
| _version_ | 1797634277210324992 |
|---|---|
| author | Dimitra Papadopoulou Fani Roumelioti Christos Tzaferis Panagiotis Chouvardas Anna-Kathrine Pedersen Filippos Charalampous Eleni Christodoulou-Vafeiadou Lydia Ntari Niki Karagianni Maria C. Denis Jesper V. Olsen Alexios N. Matralis George Kollias |
| author_facet | Dimitra Papadopoulou Fani Roumelioti Christos Tzaferis Panagiotis Chouvardas Anna-Kathrine Pedersen Filippos Charalampous Eleni Christodoulou-Vafeiadou Lydia Ntari Niki Karagianni Maria C. Denis Jesper V. Olsen Alexios N. Matralis George Kollias |
| author_sort | Dimitra Papadopoulou |
| collection | DOAJ |
| description | Synovial fibroblasts (SFs) are key pathogenic drivers in rheumatoid arthritis (RA). Their in vivo activation by TNF is sufficient to orchestrate full arthritic pathogenesis in animal models, and TNF blockade proved efficacious for a high percentage of patients with RA albeit coinducing rare but serious side effects. Aiming to find new potent therapeutics, we applied the L1000CDS2 search engine, to repurpose drugs that could reverse the pathogenic expression signature of arthritogenic human TNF–transgenic (hTNFtg) SFs. We identified a neuroleptic drug, namely amisulpride, which reduced SFs’ inflammatory potential while decreasing the clinical score of hTNFtg polyarthritis. Notably, we found that amisulpride function was neither through its known targets dopamine receptors D2 and D3 and serotonin receptor 7 nor through TNF–TNF receptor I binding inhibition. Through a click chemistry approach, potentially novel targets of amisulpride were identified, which were further validated to repress hTNFtg SFs’ inflammatory potential ex vivo (Ascc3 and Sec62), while phosphoproteomics analysis revealed that treatment altered important fibroblast activation pathways, such as adhesion. Thus, amisulpride could prove beneficial to patients experiencing RA and the often-accompanying comorbid dysthymia, reducing SF pathogenicity along with its antidepressive activity, serving further as a “lead” compound for the development of novel therapeutics against fibroblast activation. |
| first_indexed | 2024-03-11T12:05:22Z |
| format | Article |
| id | doaj.art-1d4158356be44267b7a2df77d6bc97a8 |
| institution | Directory Open Access Journal |
| issn | 2379-3708 |
| language | English |
| last_indexed | 2024-03-11T12:05:22Z |
| publishDate | 2023-05-01 |
| publisher | American Society for Clinical investigation |
| record_format | Article |
| series | JCI Insight |
| spelling | doaj.art-1d4158356be44267b7a2df77d6bc97a82023-11-07T16:25:35ZengAmerican Society for Clinical investigationJCI Insight2379-37082023-05-0189Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritisDimitra PapadopoulouFani RoumeliotiChristos TzaferisPanagiotis ChouvardasAnna-Kathrine PedersenFilippos CharalampousEleni Christodoulou-VafeiadouLydia NtariNiki KaragianniMaria C. DenisJesper V. OlsenAlexios N. MatralisGeorge KolliasSynovial fibroblasts (SFs) are key pathogenic drivers in rheumatoid arthritis (RA). Their in vivo activation by TNF is sufficient to orchestrate full arthritic pathogenesis in animal models, and TNF blockade proved efficacious for a high percentage of patients with RA albeit coinducing rare but serious side effects. Aiming to find new potent therapeutics, we applied the L1000CDS2 search engine, to repurpose drugs that could reverse the pathogenic expression signature of arthritogenic human TNF–transgenic (hTNFtg) SFs. We identified a neuroleptic drug, namely amisulpride, which reduced SFs’ inflammatory potential while decreasing the clinical score of hTNFtg polyarthritis. Notably, we found that amisulpride function was neither through its known targets dopamine receptors D2 and D3 and serotonin receptor 7 nor through TNF–TNF receptor I binding inhibition. Through a click chemistry approach, potentially novel targets of amisulpride were identified, which were further validated to repress hTNFtg SFs’ inflammatory potential ex vivo (Ascc3 and Sec62), while phosphoproteomics analysis revealed that treatment altered important fibroblast activation pathways, such as adhesion. Thus, amisulpride could prove beneficial to patients experiencing RA and the often-accompanying comorbid dysthymia, reducing SF pathogenicity along with its antidepressive activity, serving further as a “lead” compound for the development of novel therapeutics against fibroblast activation.https://doi.org/10.1172/jci.insight.165024Therapeutics |
| spellingShingle | Dimitra Papadopoulou Fani Roumelioti Christos Tzaferis Panagiotis Chouvardas Anna-Kathrine Pedersen Filippos Charalampous Eleni Christodoulou-Vafeiadou Lydia Ntari Niki Karagianni Maria C. Denis Jesper V. Olsen Alexios N. Matralis George Kollias Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis JCI Insight Therapeutics |
| title | Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis |
| title_full | Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis |
| title_fullStr | Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis |
| title_full_unstemmed | Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis |
| title_short | Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis |
| title_sort | repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis |
| topic | Therapeutics |
| url | https://doi.org/10.1172/jci.insight.165024 |
| work_keys_str_mv | AT dimitrapapadopoulou repurposingtheantipsychoticdrugamisulpridefortargetingsynovialfibroblastactivationinarthritis AT faniroumelioti repurposingtheantipsychoticdrugamisulpridefortargetingsynovialfibroblastactivationinarthritis AT christostzaferis repurposingtheantipsychoticdrugamisulpridefortargetingsynovialfibroblastactivationinarthritis AT panagiotischouvardas repurposingtheantipsychoticdrugamisulpridefortargetingsynovialfibroblastactivationinarthritis AT annakathrinepedersen repurposingtheantipsychoticdrugamisulpridefortargetingsynovialfibroblastactivationinarthritis AT filipposcharalampous repurposingtheantipsychoticdrugamisulpridefortargetingsynovialfibroblastactivationinarthritis AT elenichristodoulouvafeiadou repurposingtheantipsychoticdrugamisulpridefortargetingsynovialfibroblastactivationinarthritis AT lydiantari repurposingtheantipsychoticdrugamisulpridefortargetingsynovialfibroblastactivationinarthritis AT nikikaragianni repurposingtheantipsychoticdrugamisulpridefortargetingsynovialfibroblastactivationinarthritis AT mariacdenis repurposingtheantipsychoticdrugamisulpridefortargetingsynovialfibroblastactivationinarthritis AT jespervolsen repurposingtheantipsychoticdrugamisulpridefortargetingsynovialfibroblastactivationinarthritis AT alexiosnmatralis repurposingtheantipsychoticdrugamisulpridefortargetingsynovialfibroblastactivationinarthritis AT georgekollias repurposingtheantipsychoticdrugamisulpridefortargetingsynovialfibroblastactivationinarthritis |